The news story you are looking for has expired. A more recent related article is displayed below.

Ads by Google

Protalix Said Late-Stage Study Of Gaucher Drug Uplyso Met Primary Goals (PLX)

Oct 15, 2009 (SmarTrend(R) News Watch via COMTEX) --

10/15/2009 - Protalix BioTherapeutics Inc. (NYSE:PLX) said Thursday that a late-stage study of its Gaucher drug, Uplyso, met its primary goals. The company said that the studies showed that patients taking Uplyso had significantly smaller spleen volume, which is a symptom of the disease. The study tested two doses of intravenous Uplyso on 31 patients and last nine-months. The patients in the trial receive a dose of the drug every two weeks and the doses were either 30 milligrams per kilogram of the patient's body weight, or 60 milligrams per kilogram. The company said that patients in both groups had lower spleen volume after six months of taking doses.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Copyright (C) 2009 Comtex SmarTrend(R). All rights reserved

News Provided by COMTEX


Related terms: market, nyse, securities

Related Articles

Lexicon says IBS drug met mid-stage study goal
Nov 13, 2009
... Put a Seed Newsvine link on your own site 0 Votes 0 Comments Print Share Lexicon says IBS drug met mid-stage study goal Fri Nov 13, 2009 2:50 PM EST business, us, drug, ibs, lexicon-pharma, lexicon-pharmaceuticals Associated...

Standard Register Reports Q3 Loss
Oct 28, 2009
...customer base, improving our cost structure, and creating the framework for our new market focused business units are the primary goals for 2009," stated Joe Morgan, president and chief executive officer. "Activities for the current quarter show that we...

Lexicon says IBS drug met mid-stage study goal
Nov 13, 2009
...Article:Lexicon says IBS drug met mid-stage study goal:/n/a/2009/11/13/financial...Article:Lexicon says IBS drug met mid-stage study goal:/n/a/2009/11/13/financial...Press Lexicon says IBS drug met mid-stage study goal Friday, November 13, 2009...

Human Genome reports positive data on lupus drug
Nov 2, 2009
...hoping it would confirm positive results from a prior late-stage study. Benlysta is aimed at suppressing the immune system's...patients and took place over 52 weeks. It is the second late-stage study on the potential lupus treatment to meet key goals. Last...